4TZ Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ORIC Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.70 |
| 52 Week High | US$14.80 |
| 52 Week Low | US$6.15 |
| Beta | 1.17 |
| 1 Month Change | -1.14% |
| 3 Month Change | 3.57% |
| 1 Year Change | 19.18% |
| 3 Year Change | -25.00% |
| 5 Year Change | n/a |
| Change since IPO | -64.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4TZ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.3% | 5.5% | 1.2% |
| 1Y | 19.2% | -3.7% | 10.1% |
Return vs Industry: 4TZ exceeded the German Biotechs industry which returned -5.6% over the past year.
Return vs Market: 4TZ exceeded the German Market which returned 9.4% over the past year.
Price Volatility
| 4TZ volatility | |
|---|---|
| 4TZ Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4TZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4TZ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 112 | Jacob Chacko | www.oricpharma.com |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers.
ORIC Pharmaceuticals, Inc. Fundamentals Summary
| 4TZ fundamental statistics | |
|---|---|
| Market cap | €582.48m |
| Earnings (TTM) | -€116.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs 4TZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4TZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$119.87m |
| Earnings | -US$119.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4TZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 23:37 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ORIC Pharmaceuticals, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |